摘要
目的探讨瘦素和瘦素受体在肺腺癌组织中的表达及其与骨转移之间的关系。方法选取2008年1月到2010年1月间资料完整、病理确诊的肺腺癌患者116例，其中出现远处转移58例（转移组），未发生转移58例（对照组）。采用免疫组化法检测116例患者石蜡切片组织中瘦素和瘦素受体的表达情况，比较瘦素和瘦素受体在转移组和对照组、骨转移组和非骨转移组的表达情况，分析肺腺癌组织与骨转移组织中瘦素和瘦素受体表达的相关性，及其与患者无骨转移生存时间（BMFS）的关系。结果58例转移组患者中，瘦素高表达36例，中表达15例，低表达7例；瘦素受体高表达32例，中表达17例，低表达9例。58例对照组患者中，瘦素高表达19例，中表达24例，低表达15例；瘦素受体高表达17例，中表达16例，低表达25例。转移组和对照组瘦素和瘦素受体的表达差异均有统计学意义（P=0.006，P=0.002），骨转移组和非骨转移组原发灶中瘦素和瘦素受体的表达差异有统计学意义（P=0.029，P=0.032）。骨转移灶中瘦素和瘦素受体的中、高表达率分别为91.4%（32/35）和88.6%（31/35）。相关性分析显示，原发灶的瘦素和瘦素受体表达与骨转移灶的瘦素和瘦素受体表达呈明显正相关（r=0.612）。转移组患者中，瘦素高表达组、中表达组和低表达组患者的中位BMFS分别为14、21和47个月，瘦素受体高表达组、中表达组和低表达组患者的中位BMFS分别为13、19和27个月，差异均有统计学意义（P〈0.001，P=0.006）。结论瘦素和瘦素受体在肺腺癌和骨转移组织中呈高表达，与BMFS有关，可以作为肺腺癌发生骨转移的一个有效预测指标。
ObjectiveTo explore the association of expression of leptin and leptin receptor （LR） with bone metastasis of pulmonary adenocarcinoma.MethodsOne hundred and sixteen pulmonary adenocarcinoma patients who had complete clinicopathological data and definite pathological diagnosis in our hospital from January 2008 to January 2010 were selected. They were divided into the metastasis （n= 58） and non-metastasis （control, n=58） groups. The expressions of leptin and LR were identified by immunohistochemistry. The differences between expressions of leptin and LR in primary pulmonary adenocarcinoma tissues and metastasis, and between the groups with and without bone metastasis were analyzed. We also analyzed the correlation of leptin and LR expressed in primary adenocarcinoma and bone metastatic tissues, and the relationship between their expression levels and bone metastasis free survival （BMFS）.ResultsAmong 58 patients of the metastasis group, the cases of high, moderate and low expressions of leptin were 36, 15 and 7, respectively, and the cases of high, moderate and low expressions of LR were 32, 17 and 9, respectively. Among the 58 patients of control group, the cases of high, moderate and low expressions of leptin were 19, 24 and 15, respectively, and those of LR were 17, 16 and 25, respectively. The expressions of leptin and LR in primary pulmonary adenocarcinoma tissues of metastasis group were significantly different from those of the control group （P=0.006, P=0.002, respectively）. The expressions of leptin and LR in primary pulmonary adenocarcinoma tissues of the bone metastasis group were also significantly different from those of the non-bone metastasis group （P=0.029, P=0.032, respectively）. The high/moderate expression rates of leptin and LR in the bone-metastatic tissues reached 91.4% （32/35） and 88.6% （31/35）, respectively. The results showed that the expressions of leptin and LR in primary pulmonary adenocarcinoma tissues were positively related with their expressions in bone metastatic tissue （r = 0.612）. The median bone metastasis free survival （BMFS） of the bone metastasis groups with high, moderate and low expressions of leptin were 14, 21 and 47 months, respectively, and the median BMFS of high, moderate and low expressions of LR in the bone metastasis group were 13, 19 and 27 months, respectively. The expressions of leptin and LR in pulmonary adenocarcinoma were significantly associated with BMFS （P〈0.001, P=0.006, respectively）.ConclusionsThe expressions of leptin and LR are significantly up-regulated in primary pulmonary adenocarcinoma tissues and bone metastatic tissues, and are negatively correlated with BMFS. These two molecules may be used as effective predictors of bone metastasis in pulmonary adenocarcinoma.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2016年第11期840-844,共5页
Chinese Journal of Oncology
基金
河北省自然基金面上项目（H2015206314）
关键词
肺肿瘤
瘦素
瘦素受体
肿瘤转移
预后
Lung neoplasms
Leptin
Leptin receptor
Neoplasm metastasis
Prognosis
作者简介
通信作者：冯和林．Email：fenghelin0311@126．com
